Acorda Therapeutics (ACOR) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acorda Reports First Quarter 2020 Financial Results and Provides Business Update
May 5, 2020 4:00 PM EDTINBRIJA® (levodopa inhalation powder) 1Q 2020 net revenue of $4.4 million AMPYRA® (dalfampridine) 1Q 2020 net revenue of $20.1 million Reiterates 2020 AMPYRA net revenue guidance and operating expense guidance Withdraws 2020 INBRIJA net revenue guidance due to the ongoing COVID-19 pandemic
ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided a business update and reported its financial results... More
